BDM Collective works directly with investors and with small and emerging growth companies to convert their products and IP into sustainable, viable enterprises via well-tested and successful business development strategies, capital campaign management and advisory to maximize revenue and shareholder value.

SciTech, a clinical-stage oncology-focused Pharmaceutical Company, is open for investment and partnering opportunities. SciTech’s lead drug candidate, ST-001, is currently in Phase 1 clinical trials for T-cell Non-Hodgkin Lymphoma (https://clinicaltrials.gov/study/NCT04234048). ST-001 combines a nanoparticle formulation of the active drug fenretinide with phospholipids to enable the rapid infusion of high-dose fenretinide to kill cancer cells. Due to its patented formulation, SciTech researchers have solved the bioavailability, absorption, and triglyceride toxicity challenges of past fenretinide formulations- A benefit previously unattainable. SciTech has: • IND for T-cell lymphomas • Orphan Drug Designation for several T-cell lymphomas• FDA approved Phase 1a/b clinical trial for lymphomasContact me directly for the Executive Summary and information on this funding opportunity.

Neuma Health is revolutionizing Psychedelic and Mental Health Therapy with Neuma HYDRATE, the first scientifically formulated clinical hydration drink, along with a community-based digital platform for mental well-being. Order Now at www.neuma.health.

The SnapGroove team works with investors, emerging growth companies, start-ups, and accelerators to focus on revenue and growth strategy execution. From investment raise to company launch to expansion or exit, we can provide the critical business strategy and team players until you are self-sustaining. We have developed an “Agile Business Approach” that utilize 3-month “Sprints” – very similar to Agile software development. This approach enables our clients to have a defined cost and a defined plan that doesn't go on indefinitely without results. We stay on board to help you EXECUTE each Sprint. We create high impact plans for go-to-market strategies, customer acquisition, product launch and partner or distribution channel programs. We augment your management team, both on-site and virtually to help your company grow.

Navaux, a Specialty Life Sciences Company is open for investment and partnering opportunities. With offices in Arkansas and California, Navaux is dedicated to the research, development and commercialization of novel, proprietary monoclonal antibodies, cancer diagnostic tests and therapeutics. Navaux’s patent pending Hepsin discovery allows for measuring, isolating and targeting circulating Hepsin for early cancer screening with a commercially available blood test. Pre-clinical evidence supports that the lead drug candidate, NV-001 may provide a breakthrough treatment for cancer using its Hepsin monoclonal antibodies.

PluroGen Therapeutics, LLC, is an exited biotechnology company providing clinically advanced burn, wound and skin care products. Lori and her team were instrumental in the launch, growth and successful exit of the company.

Lori Kavle was President of the US division of VastPark - the leading edge, open source Virtual World Platform with an SDK to build extensible worlds for collaboration and operations to connect your corporation remotely. VastPark, a Melbourne Australia company, specializes in 3D modeling, animation and virtual collaboration development for complex projects.

Lori was CEO of Simulations International, an IT and professional services firm that developed and commercialized simulation-based software applications for the federal government, pharmaceutical and medical device markets.

Lori was a director for Cegedim/ Dendrite (now IQVIA) for their CRM platform globally. Her role encompassed standardizing life sciences companies on an integrated CRM platform, big data analytics, and professional services to improve sales, marketing and compliance worldwide. Lori and her team were instrumental at bringing new software innovations and programs to the life science industry.

As director of US accounts, Lori was responsible for revenue generation in both the physician and hospital markets, including the vetting of new technologies that could enhance territory CRM management.